M Madeira1, L V Neto, G A B de Lima, R O Moreira, L M C de Mendonça, M R Gadelha, M L F Farias. 1. Division of Endocrinology, Department of Internal Medicine, Hospital Universitário Clementino Fraga Filho/Universidade Federal do Rio de Janeiro, Av. Brigadeiro Trompowski s/n 9 andar, Cidade Universitaria, CEP, 21044-020, Rio de Janeiro, RJ, Brazil. miguelmadeira@cremerj.org.br
Abstract
SUMMARY: Studies on body composition and bone mineral density in acromegaly have conflicting results. Our data point to an increase in lean mass, a decrease in adipose tissue, and that the anabolic effect of GH on bone is partially dependent on modifications in body composition. INTRODUCTION: The effects of growth hormone (GH) and insulin-like growth factor I (IGF-I) excess and gonadal status on bone mineral density (BMD) and body composition (BC) in acromegalic patients are uncertain. METHODS: Bone mineral density and BC were evaluated by dual-energy X-ray absorptiometry (Prodigy-GE) in 75 patients (22 men and 53 women) with acromegaly, mean age 48.9 ± 14.5 years. Acromegaly was considered "controlled" when serum IGF-I was within the specific age-adjusted reference range, and serum GH was lower than 2.5 ng/mL. Comparisons between groups were performed using unpaired t test or Mann-Whitney U test. Categorical variables were analyzed by chi-square (x (2)) test. In order to compare data of different subgroups stratified by disease activity and gonadal status, one-way analysis of variance (ANOVA) and Bonferroni post hoc analysis were performed. To evaluate the correlation between GH and IGF-I and densitometric parameters, Pearson and Spearman rank order correlation were performed, as appropriate. RESULTS: There were no differences in BMD when considering disease activity and gonadal status. Active disease and eugonadism were positively correlated to an increase in lean mass and a decrease in fat mass. After multiple linear regression, there were positive correlations between GH and Z-score at lumbar spine and between lean mass and BMD at proximal femur. CONCLUSION: Our data support that GH-IGF-I excess and eugonadism have great influence on BC modifications and that the anabolic effects of GH-IGF-I on bone are, at least in part, dependent on these alterations in body composition.
SUMMARY: Studies on body composition and bone mineral density in acromegaly have conflicting results. Our data point to an increase in lean mass, a decrease in adipose tissue, and that the anabolic effect of GH on bone is partially dependent on modifications in body composition. INTRODUCTION: The effects of growth hormone (GH) and insulin-like growth factor I (IGF-I) excess and gonadal status on bone mineral density (BMD) and body composition (BC) in acromegalicpatients are uncertain. METHODS: Bone mineral density and BC were evaluated by dual-energy X-ray absorptiometry (Prodigy-GE) in 75 patients (22 men and 53 women) with acromegaly, mean age 48.9 ± 14.5 years. Acromegaly was considered "controlled" when serum IGF-I was within the specific age-adjusted reference range, and serum GH was lower than 2.5 ng/mL. Comparisons between groups were performed using unpaired t test or Mann-Whitney U test. Categorical variables were analyzed by chi-square (x (2)) test. In order to compare data of different subgroups stratified by disease activity and gonadal status, one-way analysis of variance (ANOVA) and Bonferroni post hoc analysis were performed. To evaluate the correlation between GH and IGF-I and densitometric parameters, Pearson and Spearman rank order correlation were performed, as appropriate. RESULTS: There were no differences in BMD when considering disease activity and gonadal status. Active disease and eugonadism were positively correlated to an increase in lean mass and a decrease in fat mass. After multiple linear regression, there were positive correlations between GH and Z-score at lumbar spine and between lean mass and BMD at proximal femur. CONCLUSION: Our data support that GH-IGF-I excess and eugonadism have great influence on BC modifications and that the anabolic effects of GH-IGF-I on bone are, at least in part, dependent on these alterations in body composition.
Authors: T Ueland; E N Ebbesen; J S Thomsen; L Mosekilde; K Brixen; A Flyvbjerg; J Bollerslev Journal: Eur J Clin Invest Date: 2002-02 Impact factor: 4.686
Authors: S Longobardi; C Di Somma; F Di Rella; N Angelillo; D Ferone; A Colao; B Merola; G Lombardi Journal: J Endocrinol Invest Date: 1998-11 Impact factor: 4.256
Authors: Tirissa J Reid; Zhezhen Jin; Wei Shen; Carlos M Reyes-Vidal; Jean Carlos Fernandez; Jeffrey N Bruce; Jane Kostadinov; Kalmon D Post; Pamela U Freda Journal: Pituitary Date: 2015-12 Impact factor: 4.107
Authors: Carlos M Reyes-Vidal; Hamed Mojahed; Wei Shen; Zhezhen Jin; Fernando Arias-Mendoza; Jean Carlos Fernandez; Dympna Gallagher; Jeffrey N Bruce; Kalmon D Post; Pamela U Freda Journal: J Clin Endocrinol Metab Date: 2015-06-02 Impact factor: 5.958
Authors: J Pontes; M Madeira; C H A Lima; L L Ogino; F de Paula Paranhos Neto; L M C de Mendonça; M L F Farias; L Kasuki; M R Gadelha Journal: J Endocrinol Invest Date: 2019-08-07 Impact factor: 4.256
Authors: Agnaldo José Lopes; Débora Pedroza Guedes da Silva; Arthur de Sá Ferreira; Leandro Kasuki; Mônica Roberto Gadelha; Fernando Silva Guimarães Journal: J Phys Ther Sci Date: 2015-03-31
Authors: Sjoerd D Joustra; Ferdinand Roelfsema; A S Paul van Trotsenburg; Harald J Schneider; Robert P Kosilek; Herman M Kroon; John G Logan; Natalie C Butterfield; Xiang Zhou; Chirine Toufaily; Beata Bak; Marc-Olivier Turgeon; Emilie Brûlé; Frederik J Steyn; Mark Gurnell; Olympia Koulouri; Paul Le Tissier; Pierre Fontanaud; J H Duncan Bassett; Graham R Williams; Wilma Oostdijk; Jan M Wit; Alberto M Pereira; Nienke R Biermasz; Daniel J Bernard; Nadia Schoenmakers Journal: J Clin Endocrinol Metab Date: 2020-03-01 Impact factor: 5.958